로딩 중…
지수 로딩 중…
DONG-A ST CO.,LTD
170900· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩34,200-4.07%
2026-06-19
Price Chart
DONG-A ST CO.,LTD-24.27%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 332.69B KRW |
| Revenue | 830.27B KRW |
| Net Income | -11.94B KRW |
| Total Assets | 1.36T KRW |
| Net Assets | 681.82B KRW |
| Employees | 1,695 |
| Value | |
| P/B | 0.49x |
| P/S | 0.40x |
| EV/EBITDA | 59.90x |
| FCF Yield | 1.69% |
| Profitability | |
| ROE | -1.75% |
| ROA | -0.88% |
| Op. Margin | 1.18% |
| Revenue Growth | 11.80% |
| Earnings Growth | -173.97% |
| Financial Health | |
| Debt Ratio | 98.78% |
| Total Debt | 484.57B KRW |
| FCF | 5.64B KRW |
| Cash | 228.61B KRW |
| Current Ratio | 1.50x |
| Net Debt/EBITDA | 26.05x |
| Dividend | |
| Div. Yield | 1.87% |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | -24.27% |
| 1M Return | -14.93% |
| From 52W High | -39.43% |
| 1Y MDD | -37.96% |
| Trading | |
| Volume | 30,351 shares |
| Foreign Own. | 18.98% |
| Per Share | |
| EPS | -1,199 KRW |
| BPS | 67,799 KRW |
Company Info
Dong-A ST was established in 2013 as a spin-off from Dong-A Socio Holdings and acquired a global ADC specialist in 2023 to secure technology and pipelines. The company manufactures and sells developed new drugs such as STILLEN, Zydena, and Motilitone, along with specialized pharmaceuticals like Growtropin and Gaster, produced at its Cheonan, Daegu, and Songdo campuses. Dong-A ST is expanding R&D investment to develop new drugs for metabolic diseases including diabetes, obesity, and MASH, thereby strengthening its market dominance with a diverse portfolio. Dong-A ST is headquartered in Dongdaemun-gu, Seoul.